Antibody–drug conjugates (ADCs) were conceived to concentrate potent cytotoxics at tumour cells by linking a monoclonal antibody to a payload. Over time, deeper mechanistic insight into how ADCs work — and how tumours adapt or resist — has produced numerous advances in ADC chemistry and in rational combination strategies. The pace of these innovations, however, now exceeds the capacity of traditional clinical-trial pipelines to evaluate each change independently.
The authors argue for an integrated approach that combines multiple chemistry advances within single ADC constructs rather than evaluating isolated modifications. Such integration aims to produce more robust improvements in clinical efficacy than sequential single-parameter optimization. Complementary elements of an integrated strategy include preclinical and translational frameworks that accelerate and de-risk the progression of new constructs into early clinical studies, and infrastructural tools that enable rapid, hypothesis-driven testing.
Figures in the source summarize an integrated development strategy for maximizing ADC potential in patients, emphasizing combined chemical optimization, predictive biomarker development and strategic clinical testing pathways.
Understanding how ADCs exert antitumour effects and how tumours adapt or develop resistance is central to refining ADC design and use. Clinical and translational studies cited in the source have illuminated diverse molecular and immunological drivers that influence ADC activity. These include antigen expression and heterogeneity, intracellular trafficking and payload release, tumour penetration and single-cell targeting, and host-related factors that can modulate toxicity and response.
Clinical observations and preclinical analyses have also highlighted mechanisms that can limit ADC benefit, such as suboptimal tumour distribution, resistance pathways within cancer cells, and immune- or tissue-specific effects that contribute to adverse events. For instance, reports referenced in the article discuss potential mechanisms underlying ADC-related interstitial lung disease and the role of specific macrophage populations in lung toxicity associated with some ADCs.
A systematic effort to map mechanisms of action, adaptation and resistance in patient samples is recommended to refine lead ADC constructs. Generating multidimensional molecular profiles of tumours before and after exposure to ADCs may reveal determinants of sensitivity and resistance that can be used to select patients or to guide rational combinations.
Multiple strategies to improve ADC performance are discussed. Chemical advances — for example, engineering linkers, optimizing payloads and adjusting drug-to-antibody ratios — can increase potency, stability and the therapeutic window. At the same time, improved design to enhance tumour penetration and single-cell targeting can increase intratumour exposure and single-cell kill rates.
Rational therapeutic combinations are another pillar to increase efficacy. Combining ADCs with agents that modulate the tumour microenvironment, enhance immune activity, or target complementary pathways could produce synergistic effects. However, the source cautions that combinations and single modifications are unlikely to be transformative on their own; instead, careful selection and integration of complementary enhancements are needed.
Clinical and preclinical examples cited in the article demonstrate both successes and limitations of different strategies, including topoisomerase I inhibitor–based ADCs and ADCs targeting novel antigens. These examples underscore the need to consider both efficacy and safety implications when designing combinations or next-generation constructs.
The authors call for a strategic framework to accelerate ADC clinical research and to broaden patient benefit. Key elements include:
Developing infrastructures and tools to de-risk early-stage ADC development and to prioritize constructs most likely to succeed in patients.
Creating multidimensional molecular predictors of ADC sensitivity to improve patient selection and enable personalized treatment strategies.
Testing new ADCs earlier in the disease course (for example, in early-stage cancers) where the balance of tumour burden, immune competence and toxicity risk may allow greater clinical benefit.
Building diversified ADC libraries that incorporate distinct constructs and varied drug-to-antibody ratios, allowing tailoring of ADC properties to specific tumour biology.
The source emphasizes that these approaches require coordination across preclinical modelling, translational biomarker studies and adaptive clinical testing to keep pace with chemical innovation. It also highlights that a long-term goal is to enable personalized ADC strategies through matched libraries of constructs aligned to individual tumour characteristics.
In summary, the perspective argues that the next generation of ADCs will be defined not by single incremental changes but by integrated constructs, predictive molecular tools and enabling infrastructures that speed and de-risk translation. Combining multiple chemistry innovations, improving mechanistic understanding from patient-derived data, and developing frameworks for early clinical evaluation and personalization are proposed as essential steps to expand the clinical impact of ADCs in oncology.
Figures referenced in the source provide visual summaries of an integrated development strategy (Fig. 1), mechanisms of ADC action and resistance (Fig. 2), strategies to enhance efficacy and combinations (Fig. 3), and a strategic framework to accelerate clinical research (Fig. 4). Details on specific study outcomes, quantitative results and trial data were not reported in the previewed source content provided here.